REGN News and Press, Regeneron Pharmaceuticals Inc. From 12/14/23

2023-12-14 13:56:03 ET Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference Call December 14, 2023, 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations George Yancopoulos - Board Co-Chair, Co-Founde...

2023-12-14 12:25:24 ET Summary Biopharmaceutical sector valuations have become more attractive after a significant decline in 2021. Larger drug companies are making acquisitions and partnerships with small-cap stocks at generous premiums. Money managers are under-invested in t...

2023-12-14 09:00:00 ET You shouldn't have to keep a close eye on your investments. If you find solid stocks to buy, you can leave them in your portfolio and simply wait for their operations to grow and become larger over time, leading to potentially great returns in the long run. Three ...

2023-12-12 08:25:49 ET Summary Corvus Pharmaceuticals is a clinical-stage company with potential investment opportunities and a focus on the ITK inhibitor soquelitinib. The company is targeting relapsed peripheral T-cell lymphoma with plans to begin a Phase 3 clinical trial early ...

TARRYTOWN, N.Y., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its inclusion on the Dow Jones Sustainability World Index (DJSI World) for the fifth consecutive year, alongside its fourth consecutive inclusion on the Dow Jones Sustainability North...

2023-12-11 06:01:35 ET Regeneron Pharmaceuticals ( NASDAQ: REGN ) on Sunday presented updated trial data for its bispecific lymphoma antibody, odronextamab, in patients with relapsed/refractory (R/R) follicular lymphoma (FL). Odronextamab is currently under regulatory review...

Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR Oral presentation showcased overall maintenance of patient-reported outcomes from baseline to 50 ...

Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort showed a 48% ORR and 30% CR in patients who had progressed on CAR-T Additional exp...

2023-12-08 15:00:12 ET More on the markets S&P 500: New All-Time Highs Before A Major Sell-Off S&P 500 Forecast 2024: Muddling Through Only Thing That Matters Is Price; Nasdaq Has Further To Go - Cestrian Capital Research Money market funds attract mo...

2023-12-08 07:45:00 ET Regeneron Pharmaceuticals (NASDAQ: REGN) is a top pharmaceutical company with many promising assets in its portfolio. Its diverse business has enabled the business to grow over the years. In the past decade, the stock has risen by more than 185%, outperforming...